Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03388762 · ClinicalTrials.gov registry record · NA

RCT of a Polyherbal Dietary Supplement for Prediabetes

A NA study of Prediabetic State, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
39
Enrollment target
4
Study locations

NCT03388762: Completed NA study of Prediabetic State, sponsored by University of Maryland, Baltimore.

NCT03388762 is a NA study of Prediabetic State that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 39 participants, below the 563-participant average among 23 other Prediabetic State trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03388762, a NA study of Prediabetic State, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
4
Study locations

Study Summary

The primary purpose of this study is to evaluate the impact of a polyherbal dietary supplement (Designs for Health - GlucoSupreme™ Herbal) on markers of glycemic control and other structure/function outcomes among a sample of prediabetic adults. A 12-week randomized, double-blinded, placebo-controlled clinical trial will be conducted to achieve the purpose of this study. The research team hypothesizes that GlucoSupreme™ Herbal will improve a variety of validated markers of glycemic control that are commonly used in clinical practice more effectively than placebo.

Primary Outcome

Elevated fasting blood glucose is one of the markers of the prediabetic state. According to American Diabetes Association criteria, the prediabetic fasting blood glucose range is 100 to 125 mg/dL (5.6 to 6.9 mmol/L). After fasting for 8-12 hours, \> 0.5mL of blood will be collected from each participant, followed by centrifuge separation of plasma from cells within 45 minutes of collection. After maintaining the plasma fasting blood glucose at room temperature, it will be analyzed using standard

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT GlucoSupreme™ Herbal

Study Locations (4)

Maryland

  • University of Maryland Center for Diabetes and Endocrinology - Baltimore
  • University of Maryland Family Medicine Associates - Baltimore
  • University of Maryland School of Medicine, Department of Family and Community Medicine, East Hall - Baltimore

Ohio

  • Alliance Integrative Medicine - Cincinnati

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2017-12-05
Est. Completion 2020-01-01
Phase NA
University of Maryland, Baltimore

560 total trials

What the finished NCT03388762 record still lists

NCT03388762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 563-participant average among 23 other Prediabetic State trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Prediabetic State appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03388762 reports a single indexed study location in Maryland, Ohio.

Frequently Asked Questions

What is clinical trial NCT03388762 about?

NCT03388762 is a clinical study titled "RCT of a Polyherbal Dietary Supplement for Prediabetes". The primary purpose of this study is to evaluate the impact of a polyherbal dietary supplement (Designs for Health - GlucoSupreme™ Herbal) on markers of glycemic control and other structure/function outcomes among a sample of prediabetic adults. A 12-week randomized, double-blinded, placebo-control...

What is the current status of trial NCT03388762?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2017-12-05. Estimated completion is 2020-01-01.

What conditions does trial NCT03388762 study?

This clinical trial studies the following conditions: Prediabetic State.

What interventions are being tested in trial NCT03388762?

The interventions under investigation include: Placebo (OTHER), GlucoSupreme™ Herbal (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03388762?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03388762 being conducted?

This trial has 4 study locations across Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prediabetic State

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03388762's enrollment target sits among peer trials

39 19th of 23 higher than 5 of 23 other Prediabetic State trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prediabetic State trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03388762, the US trial registry maintained by the National Library of Medicine. NCT03388762 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.